SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056953
Filing Date
2024-05-09
Accepted
2024-05-09 16:10:53
Documents
69
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q alxo-20240331.htm   iXBRL 10-Q 1954965
2 EX-31.1 alxo-ex31_1.htm EX-31.1 16384
3 EX-31.2 alxo-ex31_2.htm EX-31.2 16586
4 EX-32.1 alxo-ex32_1.htm EX-32.1 9378
5 EX-32.2 alxo-ex32_2.htm EX-32.2 9392
  Complete submission text file 0000950170-24-056953.txt   7392314

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alxo-20240331.xsd EX-101.SCH 958876
73 EXTRACTED XBRL INSTANCE DOCUMENT alxo-20240331_htm.xml XML 1202553
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

IRS No.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39386 | Film No.: 24930677
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)